A case of generalized psoriasiform and pustular eruption induced by infliximab: Evidence for skin-homing Th17 in the pathogenesis

British Journal of Dermatology

Volumn 163, Issue 6, 2010, Pages 1347-1351

  Teraki, Y ^a   Tanaka, S ^a   Hitomi, K ^a   Izaki, S ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

CCR4; cutaneous lymphocyte associated antigen; IL 17; IL 22; psoriasiform and pustular eruption; Th17; tumour necrosis factor inhibitor

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR4; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 22; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; ANKLE; BUTTOCK; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; ERYTHEMA; FEMALE; FEVER; FLOW CYTOMETRY; FOOT SOLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LEUKOCYTE COUNT; LIMB; LYMPHOCYTE HOMING; NEUTROPHIL COUNT; PATHOGENESIS; PHENOTYPE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; PUSTULE; RHEUMATOID ARTHRITIS; SKIN ABSCESS; SKIN BIOPSY; T LYMPHOCYTE; TH17 CELL; TRUNK;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-17; INTERLEUKINS; MIDDLE AGED; PHENOTYPE; PSORIASIS; RECEPTORS, LYMPHOCYTE HOMING; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649673609     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10002.x     Document Type: Letter

References (10)

1. De Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-31.
2. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-91.
3. Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009; 61: 486-504.
4. Ko JM, Gottlieb AB, Kerbleski JF,. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009; 20: 100-8.
5. Teraki Y, Shiohara T,. IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol 2003; 112: 609-15.
6. Kupper TS, Fuhlbrigge RC,. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-22.
7. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159: 1092-102.
8. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
9. Kabashima R, Sugita K, Sawada Y, et al. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol 2010; Jun 21 [Epub ahead of print].
10. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009; 129: 79-88.